Brief: Cyclerion Therapeutics Says Closed Enrollment For Olinciguat Phase 2 Strong Scd Study For Sickle Cell Disease Topline Data Readout Expected Q3 2020
10/04/2020 16:09
April 10 (Reuters) - Cyclerion Therapeutics Inc CYCN.O :
* CYCLERION THERAPEUTICS INC - CLOSED ENROLLMENT FOR
OLINCIGUAT
PHASE 2 STRONG SCD STUDY FOR SICKLE CELL DISEASE; TOPLINE DATA
READOUT EXPECTED Q3 2020
* CYCLERION THERAPEUTICS INC - CLOSED ENROLLMENT FOR IW-6463
TRANSLATIONAL PHARMACOLOGY CLINICAL STUDY; TOPLINE DATA READOUT
EXPECTED MID-YEAR 2020
* CYCLERION THERAPEUTICS INC - COMPANY CONTINUES DISCUSSIONS
TO
OUT-LICENSE PRALICIGUA
* CYCLERION THERAPEUTICS - AS OF MAR 31, CYCLERION'S
PRELIMINARY
UNAUDITED CASH, CASH EQUIVALENTS AND RESTRICTED CASH BALANCE WAS
ABOUT $72 MILLION
* CYCLERION THERAPEUTICS INC - ANTICIPATES THAT CASH WILL
FUND ITS
OPERATIONS INTO Q2 2021
Source text for Eikon: ID:nGNX5Qtfd6
Further company coverage: CYCN.O
((Reuters.Briefs@thomsonreuters.com;))